key: cord-0756581-oylw9a05
authors: Umubyeyi Nyaruhirira, Alaine; Scholten, Jerod N.; Gidado, Mustapha; Suarez, Pedro G.
title: COVID-19 Diagnosis in Low- and Middle-Income Countries: the big new bully disrupting TB and HIV diagnostic services
date: 2022-02-03
journal: J Mol Diagn
DOI: 10.1016/j.jmoldx.2021.12.008
sha: 3b6c50a509858f69531a74fc0c52ea14cf8c1a92
doc_id: 756581
cord_uid: oylw9a05

COVID-19 undermines control of other infectious diseases. Diagnostics are critical in health care. This opinion paper explores approaches for leveraging diagnostics for COVID-19 while retaining diagnostics for other infectious diseases including tuberculosis (TB) and HIV. We reflect on experiences with GeneXpert technology for TB detection and opportunities for integration with other diseases. We also reflect on benefits and risks of integration. Placement of diagnostics in laboratory networks is largely non-integrated and designated for specific diseases. Restricting the use of diagnostics leaves gaps in detection of TB, HIV, malaria and COVID-19. Integrated laboratory systems can lead to more efficient testing while increasing access to critical diagnostics. However, we have observed that HIV diagnosis within the TB diagnostic network displaced TB diagnosis. Subsequently, COVID-19 disrupted both TB and HIV diagnosis. WHO-recommended rapid molecular diagnostic networks for infectious diseases need more investment to achieve diagnostic capacity for TB, HIV, COVID-19 and other emerging infectious diseases. Integrated laboratory systems require mapping laboratory networks, assessing needs for each infectious disease, and identifying resources. Otherwise, diagnostic capacity for one infectious disease may displace another. Further, not all aspects of optimal diagnostic networks fit all infectious diseases, but many efficiencies can be gained where integration is possible.

The roll-out of new technologies and the substantial growth in political and financial commitment by countries, regions, and bilateral and international donors (such as the Global Fund to Fight AIDS, Tuberculosis and Malaria; President's Emergency Plan for AIDS Relief [PEPFAR] ; and US Agency for International Development) and their global partners have facilitated a surge of global progress in health over the past 15 years. 1 Despite major progress in the global HIV and tuberculosis (TB) responses, however, these diseases continue to represent a public health burden in all regions, with inequitable coverage of diagnosis, prevention, and treatment. 2 Globally, an estimated 10 million people fell ill with TB in 2019, a number that has been declining very slowly in recent years, although, in 2019, there was an estimated reduction of 1.2 million TB deaths among HIV-negative people. 3 Access to TB treatment has grown from 6 million in 2015 to 7.1 million in 2019, with increased access to TB preventive treatment as well, to 4.1 million. 4 New HIV infections among women aged 15-24 years fell by 25% between 2010 and 2018, and since 2010, AIDS-related mortality has declined by 33%. 5 Other diseases, such as hepatitis C and sexually transmitted diseases, have gained global prominence, with many low-and middleincome countries (LMICs) beginning to implement services to reduce morbidity and mortality.

The COVID-19 pandemic has created unprecedented disruptions of health services due to cases overburdening the health system or response measures that limit normal health program activities and care-seeking. As of 14 Effective interventions and services must be targeted to the most vulnerable individuals and populations-for example, pregnant women, young children, people living with HIV/AIDS or TB, the poor, and the elderly-while maintaining quality and efficiency in existing health programs. 6 As countries make progress toward universal health care (UHC), diagnostics are a critical component of health benefits packages, because most diseases or conditions cannot be managed without a clear diagnosis and laboratory tests for follow-up. COVID-gaps in detection of TB, HIV, and other opportunistic infections due, on one hand, to lack of laboratory capacity (e.g., physical infrastructure and human resources) in some LMICs even before the pandemic; and, on the other hand, to mitigation strategies undertaken to respond to COVID-19 7, 8 . These mitigation steps and shifting of resources have drastically reduced the capacity of health systems in LMICs to respond to other health issues because of overwhelmingly high demand for the care of patients with COVID-19 and interruptions within the supply chain.

Because the diagnostics have been built and funded specifically for certain diseases, the use of new advances that enable technology designed for one disease to detect other diseases is often not permitted. For example, GeneXpert, a technology that revolutionized TB molecular diagnostic testing and has a massive footprint in 145

LMICs, can now be used for HIV (viral load, early infant diagnosis) and COVID-19 testing through the recent release of the new Xpert Xpress SARS-CoV-2 cartridge.

However, financial and operational barriers generate concerns about how the utilization of this technology in weak laboratory systems and public health programs will undermine, for example, TB and HIV diagnostic capacity in some countries. If not done properly, this integration of technology could lead to suboptimal diagnosis and ultimately greater TB and HIV mortality. The newly introduced diagnostics need to be integrated in a phased, systematic manner and optimized to meet program needs and targets for both existing diseases and new ones. 4, 5, 6, 7, 8 

Application of nucleic acid amplification tests (NAATs) has revolutionized rapid and accurate diagnostic testing for most pathogens for a decade. Automated batched or modular cartridge-based NAATs offer a combination of excellent sensitivity and specificity and reproducible, accurate test results, with minimal manipulation and decreased risk of cross-contamination, that has made polymerase chain reaction (PCR) technology an appealing alternative to culture-or immunoassay-based testing for disease diagnosis. While NAATs are more sensitive than most other tests for TB, culture remains the gold standard; however, culture can take months, whereas NAATs can be performed in less than 2 hours [Stop TB Partnership. Implementation of ERPDapproved Molecular Tests for Detection of TB and Resistance to rifampicin and isoniazid: Stop TB Information note (ERPD approved TB diagnostics info note.pdf, last accessed 1/25/2022 and. 9,10,11 ) The opportunity for decentralization to lower levels of the health system makes NAATs an essential tool to carry out the End TB Strategy and realize the UNAIDS 95-95-95 goals. 12 For the past 10 years, the Xpert assay has represented the first major advance in TB diagnosis, allowing peripheral detection of rifampicin resistance, which enabled detection of drug-resistant TB and exponentially increased the numbers of cases Countries are not procuring enough cartridges to reach testing targets or fully utilize instruments due to algorithms' constraints on implementation, weak specimen referral linkages to testing, and inadequate attention to maintenance and prompt repair. To control the spread of COVID-19, experts agree that an aggressive strategy of vaccination along with Test, Trace, and Treat is needed, combine with physical distancing measures and the use of masks. However, SARS-CoV-2 detection in some countries is limited by weak and uncoordinated laboratory systems as well as insufficient laboratory equipment and test kits for PCR or access to RDT. This insufficient capacity compels governments, for example, to restrict testing to individuals who meet specific narrow criteria. 13 Many efforts and partnerships to increase the response to COVID-19 in Africa and around the world have been launched, such as the Access to COVID-19 Tools Accelerator, which is coordinated by the Global Fund, WHO, UNICEF, and the Partnership to Accelerate COVID-19 Testing in Africa. However, after 19 months in the pandemic, lessons and progress in diagnostic pipelines are demonstrating the efficiency of Ag Test and GF is advocating for using Ag test (3USD rather than GX for COVID-19 at 20 USD) and WHO is updating its Ag RDT guidance as well as preparing interim guidance on Recommendations for National SARS-CoV-2

Testing Strategies and Diagnostic Capacities.

This paper aims to identify the best approach to using both existing and new technologies to address the COVID-19 pandemic and co-existing major public health challenges without jeopardizing the gains in diagnostic access for TB, HIV, and other opportunistic infections.

COVID-19 illustrates our common vulnerability to disease across borders; the publicprivate divide; and the limits of our fragmented approach to health. 2,11,12,13 A more coordinated, comprehensive, and integrated decentralization of services at the community level is urgently needed. In their paper, Pooran et al. makes a case for value for money for point of care TB diagnostic services as reduces death but also economic loss in Africa. It also reduces transport costs to have testing done more locally. 11 Governments and donors will need to revisit public health programs and systems in line with UHC in LMICs. Doing so will require a paradigm shift, with change management, J o u r n a l P r e -p r o o f Given these developments, the diagnostic pipeline for COVID-19 and other priority diseases is growing. Integrated technologies, such as next-generation sequencing, at peripheral levels might also be used for detection of drug resistance across diseases.

Furthermore, treatment monitoring, such as viral load and bacterial load testing, might also be conducted using integrated platforms. Having well-functioning laboratory systems to detect multiple infectious diseases, their drug resistance patterns, and treatment responses at lower levels of the health system would enable a more equitable, people-centered approach, with increased access and decreased turn-around time, ultimately reducing morbidity and mortality from infectious disease, particularly TB and HIV. 8, 14, 16, 17 but such integration has not been done in the same manner across countries, and we have learned lessons about how it could be better done in the future.

We believe that no one size fits all, as countries vary in infrastructure, disease burden, and geographic peculiarities. Further, some countries have vector-borne diseases such as malaria and cholera that are relevant only in certain areas of the country.

Nonetheless, many common links can be made across most LMICs to integrate their laboratory systems for infectious diseases and create a more resilient response on all tiers of their public health laboratory network, shifted closer to and targeted to the communities that need them.

LMICs should take advantage of existing multiplex platforms, such as GeneXpert, highthroughput platform technologies, and laboratory networks, to introduce COVID-19 testing, because these networks are already established and working well to make laboratory diagnostic services available in these countries. By integrating diagnostics for COVID-19 and other infectious diseases into a well-articulated laboratory system, we will not only gain efficiencies but also move closer to UHC even during the COVID-19 pandemic. Introducing a vertical COVID-19 diagnostic service model would be expensive and inefficient in reaching the people who need the services-and it would not be sustainable.

Integrated, affordable multiplex technologies, particularly at the point of care and local and community levels, have the advantages of avoiding parallel diagnostic systems and duplication of activities such as referral and transport, equipment maintenance, human resource management, quality assurance, supply chain and quantification, and training-and duplication of the costs of those activities. In providing increased capacity and uptake for TB, HIV, COVID-19, and other existing or future opportunistic infections, integrated technologies offer better value for money and sustainability.

Innovative approaches to diagnostic integration can maximize investments while increasing access but require a strategic approach tailored to each country context based on mapping and optimizing the laboratory network, assessing the needs for detection capacity for each disease, and identifying the gaps so resources can be mobilized. Merely having the machines will not translate into great improvements. We must also strengthen:

▪ Political leadership to remove barriers to diagnostic integration, and roadmaps and strategic plans focused on increasing investment in diagnostic capacity in a holistic, coordinated way, with robust policies;

▪ Structures for supplies of consumables, maintenance, and sample transportation;

▪ Coordination and communication among disease control programs, including donors and the private sector;

▪ Technical assistance to ministries of health, local public health programs and institutions, and the private sector;

J o u r n a l P r e -p r o o f ▪ Quality-assured, connected, and sustainable laboratory networks, led by a national public health laboratory or other governance body, to guarantee universal access to prevention, diagnostics, treatment, and care services; ▪ Integrated laboratory information systems and dashboards to increase use of data and inform decision-making for patient management, program planning, and service delivery, while ensuring confidentiality.

Effective interventions and services will require transforming our way of diagnosing and treating people to enable countries to reach the End TB milestones and UNAIDS 95-95-95 goals, even while containing other diseases. If we don't act to mitigate the threat, COVID-19 will lead to an upsurge in deaths from TB, HIV, and other opportunistic infections. If we take an integrated approach, leveraging the infrastructure and resources we have already invested in and moving swiftly to strengthen the health system as a whole, we can step up the fight against both COVID-19 and other diseases of major public health importance.

We call on all ministries of health, donors, implementers, partners, and supported countries to revisit their strategies by looking at all these opportunities. We recommend that donors focus investments in COVID-19 testing by taking advantage of existing platforms and infrastructures to maximize service coverage to save lives during the pandemic while at the same time serve as a benchmark to gauge progress towards implementing guidelines such as the WHO Essential Diagnostics List and investing in J o u r n a l P r e -p r o o f

Malaria eradication within a generation: ambitious, achievable, and necessary

Realizing the "40 by 2022" Commitment from the United Nations High-Level Meeting on the Fight to End Tuberculosis: What Will It Take to Meet Rapid Diagnostic Testing Needs? Glob Health Sci Pract

The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis

Global tuberculosis report 2020

Global AIDS update 2019: communities at the centre: defending rights, breaking barriers, reaching people with HIV services

Second round of the national pulse survey on continuity of essential health services during the COVID-19 pandemic

Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study

The Lancet Commission on diagnostics: transforming access to diagnostics, The Lancet

Tuberculosis diagnostics technology landscape

Molecular diagnostics integration global meeting report

Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation

AIDS update 2020: seizing the moment: tackling entrenched inequalities to end epidemics

Africa's struggle with inadequate COVID-19 testing

Fast, portable tests come online to curb coronavirus pandemic

Molecular detection of drug resistant malaria in southern Thailand

Leveraging a multiplex platform for TB, HIV and coronavirus for diagnostic testing and clinical monitoring: country experiences. Symposium at the 51st Global Conference for International Union against Tuberculosis and Lung Disease

Early experience in implementation of an integrated COVID-19 and TB community-based active case finding

We thank Hector Castro and Thomas Hall for their invaluable review and feedback, Barbara K. Timmons for editing support and Jordan Coriza facilitating the submission process.

long-term UHC goals. This approach will cost far less than setting up parallel systems or centralizing testing in a few laboratories. This is a time to be bold and act fast.

AUN drafted the manuscript. All authors contributed, reviewed, edited, and approved the final manuscript equally.J o u r n a l P r e -p r o o f